06887 東陽光藥
SUNSHINE PHARMA
SUNSHINE PHARMA
| Listing Date | 2025/08/07 Listing by Introduction |
| Listing Price | -- |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Sunshine Lake Pharma Co. is a vertically integrated pharmaceutical company engaging in research and development, production and commercialization of pharmaceutical products. It strategically focus on therapeutic areas of infectious diseases, chronic diseases and oncology.
--
For the years ended December 31, 2022, 2023 and 2024, its revenue from sales of anti-infective drugs, accounting for 85%, 90% and 69.6% of total revenue for the same periods, respectively.
--
Its existing anti-infective product portfolio mainly includes top-selling product, Kewei (oseltamivir phosphate), for the treatment of influenza (in particular, Type A and Type B influenza viruses), one innovative drug developed in-house, Dongweien (emitasvir phosphate), for the treatment of hepatitis C, and three generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin and Moxifloxacin Hydrochloride.
--
As of 20 June 2025, the Group had sold 48 drugs in China and 23 drugs in overseas markets. As of December 31, 2024, we have 1,884 employees engaged in marketing and educational promotion activities, covering 32 provinces, cities and autonomous regions and nearly 300 prefecture-level cities in the PRC.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 100 |
LISTING BY INTRODUCTION
| Stock Code | 6887 |
| Sponsor(s) | -- |
TIME TABLE
| Dealings in Shares commence on | Aug 07, 2025. (Thu) |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).